Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early bactericidal activity of antituberculosis agents.

P R Donald1, F A Sirgel, A Venter

  • 1Department of Paediatrics and Child Health, Faculty of Health Sciences, University of Stellenbosch, PO Box 19063, Tygerberg, 7505, South Africa.

Expert Review of Anti-Infective Therapy
|October 16, 2004
PubMed
Summary

Early bactericidal activity (EBA) measures how well tuberculosis drugs kill bacteria in the first two days. This review shows EBA is reproducible and vital for understanding drug effectiveness, with patient factors causing most result variations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"30 years of global collaboration in transplantation and cellular therapy: WMDA's commitment to donor safety, ethical standards, and equitable access".

Bone marrow transplantation·2025
Same author

Pharmacokinetics of high-dose isoniazid in children affected by multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2021
Same author

Locked down: Impact of COVID-19 restrictions on trauma presentations to the emergency department.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde·2021
Same author

Droplets, dust and guinea pigs: an historical review of tuberculosis transmission research, 1878-1940.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2018
Same author

The impact of implementing a Xpert MTB/RIF algorithm on drug-sensitive pulmonary tuberculosis: a retrospective analysis.

Epidemiology and infection·2017
Same author

Xpert(®) MTB/RIF detection of Mycobacterium tuberculosis from sputum collected in molecular transport medium.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016

Area of Science:

  • Pharmacology
  • Microbiology
  • Clinical Medicine

Background:

  • Early bactericidal activity (EBA) quantifies Mycobacterium tuberculosis log(10) colony forming units (cfu) reduction per ml sputum per day within the initial 2 days of treatment.
  • EBA assessment is a crucial preliminary step in evaluating antituberculosis agents' clinical efficacy.

Purpose of the Study:

  • To review published studies on the EBA of various antituberculosis agents.
  • To analyze the impact of EBA results on understanding agent actions.
  • To explore variations in EBA results, considering patient characteristics and sputum findings.

Main Methods:

  • Review of eight published studies on antituberculosis agents' EBA.
  • Analysis of patient demographics, clinical characteristics, and sputum findings.

Related Experiment Videos

  • Exploration of sources contributing to EBA result variability.

    • Main Results:

    • Patient factors (age, weight, sex, lung involvement, multicavitary disease) did not correlate with EBA.
    • Initial sputum log(10) cfu/ml averaged 6.474, correlating with radiological extent and cavity size.
    • Isoniazid EBA increased with higher initial cfu counts.
    • Overall EBA variation was 0.0303, with interpatient variation in disease and sputum sampling being the largest contributor (0.0212).

    Conclusions:

    • Early bactericidal activity (EBA) is a reproducible and significant investigation for understanding antituberculosis agents.
    • Interpatient variability in disease characteristics and sputum sampling are the primary drivers of variation in EBA results.
    • EBA provides valuable insights into the efficacy of both existing and novel antituberculosis therapies.